Company news
HCW Biologics Inc. news in 2025
HCW Biologics Inc.'s news releases, calls and decks from 2025, newest first.
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
November 19, 2025
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
November 18, 2025
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
November 14, 2025
HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer
November 10, 2025
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
November 7, 2025
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment
October 22, 2025
HCW Biologics to Participate in the 2025 Maxim Growth Summit
October 16, 2025
HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer
October 16, 2025
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
September 30, 2025
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
September 18, 2025
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
September 16, 2025
HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
September 9, 2025
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
August 25, 2025
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
August 18, 2025
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
June 27, 2025
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
June 26, 2025
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
June 4, 2025
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results
May 15, 2025
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
May 13, 2025
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
May 12, 2025
HCW Biologics Announces 1-for-40 Reverse Stock Split
April 1, 2025
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
March 28, 2025
HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
March 6, 2025
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
February 2, 2025
HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025
January 14, 2025